Novartis’ Entresto Patent Revived in Federal Circuit Ruling

The Federal Circuit reversed a Delaware district court’s 2023 ruling axing a Novartis Pharmaceuticals Corp. patent covering its Entresto heart drug.

The reversal is a win for Novartis, which saw its European shares and US depositary receipts drop following the 2023 opinion from the US District Court for the District of Delaware finding the patent invalid. The appellate ruling also undoes a win for MSN Pharmaceuticals Inc., which has sought to introduce a generic version of the drug.

Novartis’ US Patent No. 8,101,659 “has an adequate written description of what is claimed,” according to a precedential opinion issued Friday by ...